Microbiology & Sterility Testing
Contract microbiology labs conducting sterility, bioburden, endotoxin, and environmental monitoring testing for injectable, ophthalmic, and sterile pharmaceutical products.
Market snapshot
These figures describe Life Sciences & Pharmaceutical Testing (1.10.9), the segment that Microbiology & Sterility Testing sits within — not Microbiology & Sterility Testing on its own.
Within testing laboratories (NAICS 541380, ~$28B total) and overlapping pharma-services; the Census Bureau does not separately size this segment.
Business model & economics
Revenue model
Per-test and study fees with recurring quality-testing programs
Key economics
- Recurring revenue
- High
- EBITDA margin
- 18–30%
- Capex intensity
- High
ongoing GMP and stability testing recurs
Characteristics
- High-value, regulation-anchored testing for drug development.
- Outsourcing of pharma quality testing drives durable demand.
- Capital-intensive labs and accreditation create barriers.
M&A deal context
Who’s acquiring
- Global TIC & pharma-services majors
- CRO/CDMO acquirers
- PE-backed lab platforms
What’s driving deals
- Drug pipelines and outsourced quality testing driving growth.
- Consolidation across testing and pharma-services networks.
- Recurring, high-value GMP testing attracting buyers.
Find Microbiology & Sterility Testing acquisition targets
Search Acquisera’s index for companies classified under Microbiology & Sterility Testing (1.10.9.3) and build a targeted deal pipeline.
Search companies